𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Hormonal effects of CV 205–502, a novel octahydrobenzo [g] quinoline with potent dopamine agonist properties

✍ Scribed by R.C. Gaillard; J. Brownell

Book ID
118343084
Publisher
Elsevier Science
Year
1988
Tongue
English
Weight
471 KB
Volume
43
Category
Article
ISSN
0024-3205

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Antiparkinsonian activity of a non-ergot
Antiparkinsonian activity of a non-ergot dopamine agonist, CV 205-502, in patients with fluctuating Parkinson's disease
✍ Dr. W. Poewe; G. Luef; B. Kleedorfer; M. Emre 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 255 KB

## Abstract Six patients with fluctuating Parkinson's disease received single rising oral doses of the nonergot dopamine agonist CV 205‐502 in an open experimental study. Doses of 0.5 mg produced antiparkinsonian effects of comparable intensity but longer duration than 200 mg of L‐DOPA. CV 205‐502,

Disappearance of a pituitary tumor after
Disappearance of a pituitary tumor after 15 months of treatment with CV 205–502, a new dopamine agonist
✍ Faβbender, W. J. ;Stracke, H. ;Bachmann, G. ;Rau, W. ;Federlin, K. 📂 Article 📅 1992 🏛 Springer-Verlag 🌐 English ⚖ 482 KB

We report the case of a 27-year-old woman with a prolactin-secreting macroadenoma of the pituitary gland who was under treatment with a new dopamine agonist, Sandoz CV 205-502. Immediately after diagnosis of a 12 x 10 mm intrasellar prolactinoma, treatment with CV 205-502 was begun at a daily dose o